A copy of the research note is also available here as a pdf file: /wp-content/uploads/kei-rn-2014-3.pdf
KEI Research Note 2014:3
Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results
Elizabeth Rajasingh
November 17, 2014
On 14 March 2014, KEI published “Resurrecting the Ghost of Høsbjør Past: Global Fund seeks to establish global framework on tiered pricing enforced by WTO rules” in which we provided an analysis of the Global Fund’s plans to create a global framework for tiered pricing enforced by the rules of the World Trade Organization (WTO). Continue Reading
In the words of the International Bureau of the World Intellectual Property Organization (WIPO), the WIPO Standing Committee on the Law of Patents (SCP) was created,
created in 1998 to serve as a forum to discuss issues, facilitate coordination and provide guidance concerning the progressive international development of patent law.
On 28 October 2014, India delivered the following intervention at the WTO TRIPS Council’s annual review of the Paragraph 6 system (designed to facilitate compulsory licensing for export of pharmaceuticals).
In particular, India noted that
October 27, 2014. Bill Saporito, “Hospitals Furious at Cancer-Drug Price Hikes,” Time Magazine.
October 26, 2014. John Fauber, “FDA approves cancer drugs without proof they’re extending lives,” Journal Sentinel.
During the WIPO 2014 General Assembly’s discussions of patents and health in the context of the work of the Standing Committee on the Law of Patent (SCP), the Obama Administration embraced an aggressive position against WIPO technical assistance on the use of patent limitations and exceptions.
|
